Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 31 Show results per page	View Search Criteria \| Help With Results

Last Modified: 4/9/2008 First Published: 10/1/1999


1.		Phase I/II Pilot Study of p53 Vaccine in Patients With Adenocarcinoma of the Ovary Who Have No Evidence of Disease or Marker Disease Only

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				NCI				NCI-99-C-0137 NCI-NMOB-9903, NCI-T99-0074, T99-0074, NCT00019903

Last Modified: 7/1/2005 First Published: 3/1/2001


2.		Phase I/II Study of Immunization With Autologous In Vitro-Treated Tumor Cells and Dendritic Cells in Combination With Sargramostim (GM-CSF) in Patients With Stage IV or Recurrent Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 16				Other				HOAG-VACCINE-MEL NCI-V01-1646, NCT00012064

Last Modified: 1/14/2005 First Published: 8/1/2001


3.		Phase I/II Study of Alpha-Fetoprotein Peptide-Pulsed Autologous Dendritic Cells in HLA-A*0201-Positive Patients With Hepatocellular Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				NCI				UCLA-0001026 NCI-G01-1997, NCT00022334

Last Modified: 7/23/2007 First Published: 11/24/2002


4.		Phase I/II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides With or Without Ex Vivo CD40-Ligand Treatment in Patients With HLA-A1 and/or HLA-A2.1 Positive Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other				ERLANGEN-1490 EU-20232, NCT00053391

Last Modified: 6/27/2007 First Published: 7/23/2005


5.		Phase I/II Study of Vaccine Therapy Comprising Autologous Dendritic Cells Transfected With Autologous Polymerase Chain Reaction-Amplified Tumor RNA in Patients With Stage IV Cutaneous Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				Over 18				Other, Pharmaceutical / Industry				ERLANGEN-DERMA-ER-DC-07 EU-20513, ARGOS-ERLANGEN-DERMA-DC-07, NCT00126685


6.		A Clinical Trial That Looks at the Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients’ Own Immune Cells.

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				RDA 0466 NCT00289341


7.		Dendritic Cell Based Therapy of Malignant Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Other				MM0413 NCT00197912

Last Modified: 5/3/2006


8.		Phase II Pilot Study of Autologous T-Cell Transplantation With Vaccine-Driven Expansion of Antitumor Effectors After Cytoreductive Therapy in Patients With Metastatic Pediatric Sarcomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				35 and under at initial diagnosis				NCI				NCI-97-C-0052S NCI-T96-0038, T96-0038, NCT00019266

Last Modified: 3/1/2007 First Published: 10/1/1999


9.		Phase II Randomized Study of CD34+ Derived or Peripheral Monocyte Derived Dendritic Cells Pulsed with MART-1 and gp100 Melanoma Antigens in Patients with High Risk Stage III or Completely Resected Metastatic Melanoma (Summary Last Modified 06/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				16 and over				NCI				NCI-99-C-0132 NCT00019890

Last Modified: 6/27/2006 First Published: 8/1/2000


10.		Phase II Study of Melanoma Vaccine Comprising Autologous Dendritic Cells Pulsed With Tumor Antigen Peptides From MART-1:26-35, gp100:209-217, and Tyrosinase:368-372 and Treated Ex Vivo With CD40-Ligand and Interferon Gamma, Followed By Interleukin-2 In Vivo in HLA-A2.1 Positive Patients With Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				LAC-USC-10M991 NCI-G00-1837, NCI-T99-0102, NCT00006113, T99-0102

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute